Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 22.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults 18 years of age and above at the time of enrollment;~* Able to provide consent to participate in and having signed an Informed Consent Form (ICF);~* Able and willing to complete all the scheduled study procedures during the whole study follow-up period;~* HIV negative;~* No nasal or oral diseases, such as acute rhinitis (sinusitis), allergic rhinitis, oral ulcers, sore throat, etc;~* IgG ang IgM negative for Covid-19;~* Axillary temperature ≤37.0℃;~* No contact history of Covid-19.~Exclusion Criteria:~* Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement: systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg), etc;~* Abnormal laboratory test indicators which investigator decide to be clinically significant; (Only Phase I volunteers)~* Respiratory rate ≥17 per minute;~* Abnormal lung function such as asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, etc;~* Prior Covid-19 vaccinations;~* Symptoms of upper respiratory track infections;~* Medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders;~* History of allergies to any ingredient of Ad5-nCoV, history of serious allergic reactions to any vaccine, history of allergies and immune diseases;~* Acute febrile diseases and infectious diseases;~* Medical history of SARS (SARS-CoV-1);~* Severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc;~* Congenital or acquired angioedema/neurological edema;~* Urticaria history within 1 year before receiving the study vaccine;~* Asplenia or functional asplenia;~* Thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection);~* Trypanophobia in intramuscular injection groups;~* History of receiving immunosuppressant therapy (continuous oral or instillation for more than 14 days), anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months;~* Prior administration of blood products in last 4 months;~* Other vaccination(s) or investigational drugs within 1 month before study onset, or planned use during the study period;~* Prior administration of live attenuated vaccine within 1 month before study onset;~* Prior administration of subunit or inactivated vaccine within 14 days before study onset;~* Current anti-tuberculosis therapy;~* Women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the whole study;~* Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.) Exclusion criteria for the phase II portion of the study will be detailed in an amended synopsis/study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A1a Phase I low 2 doses (Type: EXPERIMENTAL): Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
- A1b Phase I placebo low 2 doses (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
- A2a Phase I medium 2 doses (Type: EXPERIMENTAL): Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
- A2b Phase I placebo medium 2 doses (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
- A3a Phase I high 2 doses (Type: EXPERIMENTAL): Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
- A3b Phase I placebo high 2 doses (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
- A4a Phase I combine 2 doses (Type: EXPERIMENTAL): 1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
- A4b Phase I placebo combine 2 doses (Type: PLACEBO_COMPARATOR): 6 subjects, Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
- A5a Phase I single dose (Type: EXPERIMENTAL): Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
- A5b Phase I placebo single dose (Type: PLACEBO_COMPARATOR): 6 subjects, Placebo containing 0 vp, 1 dose Aerogen Solo
- B1a Phase II low 2 doses (Type: EXPERIMENTAL): Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
- B1b Phase II placebo low 2 doses (18-59) (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
- B2a Phase II medium 2 doses (Type: EXPERIMENTAL): Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
- B2b Phase II placebo medium 2 doses (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
- B3a Phase II high 2 doses (Type: EXPERIMENTAL): Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
- B3b Phase II placebo high 2 doses (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
- B4a Phase II combine 2 doses (Type: EXPERIMENTAL): 1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
- B4b Phase II placebo combine 2 doses (Type: PLACEBO_COMPARATOR): Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
- B5a Phase II intramuscular single dose (Type: EXPERIMENTAL): Ad5-nCoV containing 5E10 vp, 1 dose Intramuscular Injection
- B5b Phase II placebo intramuscular single dose (Type: PLACEBO_COMPARATOR): placebo containing 0 vp, 1 dose Intramuscular Injection
- B6a Phase II Aerogen Solo single dose (Type: EXPERIMENTAL): Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
- B6b Phase II placebo Aerogen Solo single dose (Type: PLACEBO_COMPARATOR): placebo containing 0 vp, 1 dose Aerogen Solo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete